Stelios Papadopoulos, Ph.D., a co-founder of Exelixis, has been a director since December 1994 and the Chair of the Board since January 1998. Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in August 2006 after six years as an investment banker with the firm, where he focused on the biotechnology and pharmaceutical sectors. Prior to joining Cowen & Co., he spent 13 years as an investment banker at PaineWebber, Incorporated, where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert, where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette.
Before coming to Wall Street in 1985, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. Dr. Papadopoulos was a co-founder of Anadys Pharmaceuticals, Inc., a publicly held biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, acquired by Hoffmann-La Roche Inc. in November 2011. Dr. Papadopoulos served as a member of the board of directors of Anadys Pharmaceuticals from 2000 to 2011 and as its chairman in 2011, prior to its acquisition.
Dr. Papadopoulos has also served as a member of the board of directors of four other publicly held companies: Biogen, Inc., a biopharmaceutical company focused on the treatment of serious diseases, since 2008 and as its chairman since 2014; Regulus Therapeutics Inc., a biopharmaceutical company focused on the development of medicines targeting microRNAs, since 2008, and as its chairman since 2013; Eucrates Biomedical Acquisition Corp., a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, and as its chairman, since 2020; and BG Medicine, Inc., a diagnostics company focused on the development and commercialization of cardiovascular diagnostic tests, from 2003 until 2018. Dr. Papadopoulos was also co-founder and member of the board of directors of Cellzome Inc., a privately held drug discovery company acquired by GlaxoSmithKline in May 2012.
In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé, a member of the board of visitors of Duke Medicine, and a member of the Global Advisory Board of the Duke Institute for Health Innovation. Dr. Papadopoulos holds an M.S. in Physics, a Ph.D. in Biophysics and an M.B.A. in Finance, all from New York University.
What is Stelios Papadopoulos' net worth?
The estimated net worth of Stelios Papadopoulos is at least $28.94 million as of December 28th, 2018. Dr. Papadopoulos owns 835,073 shares of Exelixis stock worth more than $28,935,279 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Papadopoulos may own. Additionally, Dr. Papadopoulos receives a salary of $118,250.00 as Director at Exelixis. Learn More about Stelios Papadopoulos' net worth.
How old is Stelios Papadopoulos?
What is Stelios Papadopoulos' salary?
As the Director of Exelixis, Inc., Dr. Papadopoulos earns $118,250.00 per year. There are 5 executives that earn more than Dr. Papadopoulos. The highest earning executive at Exelixis is Dr. Michael M. Morrissey Ph.D., CEO, President & Director, who commands a salary of $2,160,000.00 per year. Learn More on Stelios Papadopoulos' salary.
How do I contact Stelios Papadopoulos?
Has Stelios Papadopoulos been buying or selling shares of Exelixis?
Stelios Papadopoulos has not been actively trading shares of Exelixis over the course of the past ninety days. Most recently, Stelios Papadopoulos sold 84,515 shares of the business's stock in a transaction on Tuesday, February 22nd. The shares were sold at an average price of $19.56, for a transaction totalling $1,653,113.40. Learn More on Stelios Papadopoulos' trading history.
Who are Exelixis' active insiders?
Exelixis' insider roster includes Dana Aftab (EVP), Charles Cohen (Director), Carl Feldbaum (Director), Maria Freire (Director), Maria Freire (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.
Are insiders buying or selling shares of Exelixis?
In the last year, Exelixis insiders bought shares 4 times. They purchased a total of 735,409 shares worth more than $15,270,038.49. In the last year, insiders at the biotechnology company sold shares 22 times. They sold a total of 783,864 shares worth more than $21,654,310.33. The most recent insider tranaction occured on November, 18th when EVP Patrick J Haley sold 41,588 shares worth more than $1,428,963.68. Insiders at Exelixis own 2.9% of the company.
Learn More about insider trades at Exelixis. Information on this page was last updated on 11/18/2024.
